Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells

Gemcitabine (GEM) is the front-line standard chemotherapy used for the treatment of pancreatic cancer; however, chemoresistance to GEM remains the major obstacle to the successful control of this disease. Both the expression levels and activity of aldehyde dehydrogenase 1A1 (ALDH1A1) are important f...

Descripción completa

Detalles Bibliográficos
Autores principales: DUONG, HONG-QUAN, HWANG, JAE SEOK, KIM, HEE JEONG, KANG, HYO JIN, SEONG, YEON-SUN, BAE, INSOO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2012
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508685/
https://www.ncbi.nlm.nih.gov/pubmed/22710732
http://dx.doi.org/10.3892/ijo.2012.1516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508685/
https://www.ncbi.nlm.nih.gov/pubmed/22710732
http://dx.doi.org/10.3892/ijo.2012.1516

Ejemplares similares